Evecxia Licenses Additional IP from NUS, NUH and NTU in Singapore

Evecxia, Inc., a privately funded, clinical stage biopharmaceutical company, today announced that it has licensed exclusive, world-wide rights to develop and commercialize novel formulations for improving the bioavailability and pharmacokinetics of 5-hydroxytryptophan (5-HTP) from:

  • National University of Singapore (NUS), acting through its Duke-NUS Medical School (Duke-NUS)
  • National University Hospital (NUH)
  • Nanyang Technological University, Singapore (NTU), through its innovation and enterprise company NTUitive Pte. Ltd

The joint intellectual property licensed from NUS-NUH-NTU was developed using funding from the National Health Innovation Centre Singapore (NHIC) under its Innovation to Develop (I2D) grant scheme.

This license agreement with DUKE-NUS, NUH and NTUitive strengthens our patent portfolio with additional protection, geographic coverage, and years of exclusivity to EVX-101, our lead product candidate, said John Kaiser, CEO of Evecxia.

Under the terms of the agreement, Evecxia will immediately assume full development and commercialization of EVX-101 and any other product candidates emanating from the license agreement with Duke-NUS, NUH and NTU. In addition to an upfront licensing fee Duke-NUS, NUH and NTU will receive milestone and low single-digit royalty payments.

About Evecxia

WANT TO BUILD A FINANCIAL EMPIRE?

Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

Evecxia Inc. is a privately funded, clinical stage pharmaceutical company co-founded by Duke neuropsychopharmacologists, Dr. Marc Caron and Dr. Jacob Jacobsen. Evecxia is located in the Research Triangle Park, NC. Evecxia’s primary mission is to develop and commercialize EVX-101 to treat patients suffering from disabling, common, and costly neuropsychiatric conditions in which current therapies, in many cases, are sub-optimal.

Evecxia is the first company dedicated to realizing the therapeutic potential of 5-HTP via specialized prescription combinations and drug delivery dosage forms.

About EVX-101

EVX-101 is a proprietary oral slow-release formulation of 5-HTP and low-dose carbidopa. Initially, EVX-101 will be developed and positioned as a first-choice adjunctive treatment in depressed patients responding inadequately to conventional antidepressants. As an antidepressant, the development of EVX-101, a new chemical entity (NCE), is uniquely de-risked because the therapeutic mechanismelevating extracellular serotonin beyond the effect of conventional SSRI/SNRI antidepressantsenjoys human proof-of-concept (POC) for efficacy and safety.

For more information about the Company and its product candidate, visit www.evecxia.com or contact [email protected].

Evecxia, Inc.
John Kaiser, CEO
[email protected]